- Home
- Products
- Customized FluoroAb™
- GUCY2C
- Anti-GUCY2C MAb (Clone 4)-iFluor® 532 Succinimidyl Ester
Anti-GUCY2C MAb (Clone 4)-iFluor® 532 Succinimidyl Ester (CAT#: WJY0-LS13262)
- TARGET
- ANTIBODY
- DYE
- Name
- GUCY2C
- Alternative Names
- GUCY2C; DIAR6; GUC2C; MECIL; MUCIL; STAR; guanylate cyclase 2C; GC-C
- Overview
- Human Anti-GUCY2C IgG1-kappa (Clone 4)
- Species Reactivity
- Human
- Name
- iFluor® 532 Succinimidyl Ester
- Color
- Green
- Excitation⁄Emission (nm)
- 537/560
- Detection method
- Fluorescent
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for WJY0-LS13262. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Target
| CAT# | Product Name | Linker | Payload |
| ADC-W-209 | Anti-GUCY2C-VC-MMAE ADC | VC (valine-citrulline) | MMAE (Monomethyl auristatin E) |
| ADC-W-210 | Anti-GUCY2C-Mc-MMAF ADC | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
| ADC-W-403 | Anti-GUCY2C-MMAE ADC | Cleavable peptide linker | MMAE (Monomethyl auristatin E) |
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Anti-CD22 MAb (Clone 31)-iFluor® 450 Succinimidyl Ester (CAT#: WJY0-LS7036)
- Anti-ITIH4 MAb (Clone 1)-iFluor® 430 Succinimidyl Ester (CAT#: WJY0-LS3422)
- Anti-TNFRSF9 MAb (Clone 11)-iFluor® 546 Succinimidyl Ester (CAT#: WJY0-LS15373)
- Anti-TAG-72 MAb (Clone 3)-iFluor® 532 Succinimidyl Ester (CAT#: WJY0-LS13062)
- Anti-NRP1 MAb (Clone 1)-iFluor® 546 Succinimidyl Ester (CAT#: WJY0-LS14520)
- Anti-MET MAb (Clone 21)-iFluor® 488 Succinimidyl Ester (CAT#: WJY0-LS10642)
- Vepalimomab-OGreen (CAT#: ADC-FL-089)
- Anti-MET MAb (Clone 16)-iFluor® 440 Succinimidyl Ester (CAT#: WJY0-LS6023)
- Lucatumumab-PBlue (CAT#: ADC-FL-774)
- Anti-NGF MAb (Clone 1)-iFluor® 555 Succinimidyl Ester (CAT#: WJY0-LS16055)
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.
